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Abstract
Purpose To evaluate photopic negative response
(PhNR) discrimination ability between healthy and
glaucomatous patients.
Methods Ninety eyes of 50 patients with primary
open angle glaucoma (POAG) and 45 eyes of 23
healthy age- and sex-matched controls were investi-
gated. Based on European Glaucoma Society criteria,
POAG patients were divided into three groups: early,
moderate and advanced glaucoma. Following mea-
surements were analysed: mean defect (MD) from
Humphrey Visual Field Analyzer, SITA standard 24-2
white on white perimetry; nerve fibre index (NFI)
obtained from scanning laser polarimetry; and GDx
and PhNR amplitude and PhNR/b-wave ratio. PhNR
was elicited by red stimuli with flash strength of
1.6 cd s/m2 on blue background of 25 cd/m2. Corre-
lations between retinal ganglion cells function
(PhNR), retinal sensitivity (MD) and structure (NFI)
were calculated. Sensitivity and specificity of PhNR
parameters were calculated with standard formulas.
Receiver operating characteristic (ROC) curves were
used to determine optimal cut-off values. The area
under the curve (AUC) was used to compare the ROC
curves results between PhNR amplitude and ratio.
Results PhNR amplitude and ratio were significantly
reduced in early, moderate and advanced glaucoma
groups compared to controls. The sensitivity and
specificity to detect glaucoma in early POAG were
equal to 53.3 and 90.0 % for PhNR amplitude and
60.0 and 70.0 % for PhNR ratio; in moderate POAG
63.3 and 80.0 % for PhNR amplitude and 60.0 and
86.7 % for PhNR ratio; and in advanced POAG 76.6
and 80.0 % for PhNR amplitude, 90.0 and 73.3 % for
PhNR ratio. There were no significant differences
between AUC for PhNR amplitude (0.76–0.86) and
PhNR ratio (0.78–0.86), p[ 0.05. PhNR amplitudes
and ratios correlated significantly with MD measured
by SAP and NFI obtained from GDx (p\ 0.05).
PhNR amplitude significantly decreases with
advancement of visual field defects in glaucoma
patients.
Conclusions PhNR reveals dysfunction of RGCs in
early, moderate and advanced stage of POAG. PhNR
has good discrimination ability in detecting glauco-
matous patients. PhNR might be a useful test in
glaucoma diagnosis.
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Introduction
According to the World Health Organization, glau-
coma is the second leading cause of preventable blind-
ness globally [1]. Glaucoma diagnosis is still based on
fundus examination, intraocular pressure (IOP) mea-
surements and visual field testing. In many patients,
visual field losses become detectable after a substan-
tial number of RGCs has been lost [2, 3]. Previous
studies have reported [3, 4] that repeatable defects in
static visual field perimetry results occurred when at
least 25–50 % of RGC had been lost. Damage of the
RGCs is assessed with the use of imaging technolo-
gies. Optical coherent tomography (OCT) and GDx
(scanning laser polarimetry) measure retinal nerve
fibre layer (RNFL) thickness and can capture early
morphological changes [5–7].
On the other hand, not only morphological changes,
but also function of RGCs is important in glaucoma
diagnosis and treatment. It is crucial to identify
patients with early dysfunction of RGCs, before visual
field loss and RGC damage occur.
It is possible to asses RGCs function with PhNR.
PhNR is a negative-going wave that follows the
b-wave of the photopic electroretinography. PhNR
amplitude reflects averaged function of retinal gan-
glion cells (RGCs) population [8–10]. Viswanathan
et al. [8] showed the reduction of this negative wave in
mammals with experimental glaucoma (argon laser
induced) and after tetradotoxin (TTX-sodium chan-
nels blocker) injection. Only few study results proved
that PhNR amplitude in primary open angle glaucoma
patients was reduced and this decrease in amplitude
correlated with the degree of optic nerve damage
represented by visual field loss [9–14]. However,
Cursiefen et al. [15] suggested that PhNR could not
distinguish so easy between glaucoma and healthy
patients as it was previously showed on macaques.
That is why we decided to investigate discrimina-
tion ability of PhNR parameters in glaucomatous
patients with different stages of POAG.
Methods
Subjects
Ninety eyes of 50 patients with POAGwere enrolled in
the study. They were recruited from ophthalmological
outpatient clinics in Stettin, Poland. The diagnosis of
POAG was based on glaucomatous disc morphology
associated with visual field defects, measured by static
automated perimetry (SAP, Humphrey Visual Field
Analyzer, Model 750; Humphrey Instruments, San
Leonardo, CA). The SITA standard strategy was
applied to program 24-2 white on white (W–W)—
mean defect (MD) was analysed. The visual field
defect was described as glaucomatous based on
European Glaucoma Society (EGS) guidelines [16]
and classified into one of the three groups:
early (MD[-6 dB), moderate (-12 dB\MD B
-6 dB) and advanced (MD\-12 dB) visual field
defect. Three control groups for each glaucoma
severity were selected from 45 eyes of 23 healthy
controls. Both eyes were included in the study. Each
control group consisted of 30 eyes sex-, refractive- and
age-matched normal volunteers.
Optic nerve assessment was performed with scan-
ning laser polarimetry with a version to variable
corneal compensation (Gdx-VCC; Carl Zeiss Meditec,
Inc., Dublin, CA). From GDx parameters, retinal
nerve fibre indicator (NFI) was chosen to be analysed,
because according to the literature it differentiates
with the highest sensitivity and specificity between
normal and glaucomatous patients [17, 18]. Patients’
characteristic is shown in Table 1.
All patients gave and signed informed consent. The
study was conducted according to the tenets of the
Declaration of Helsinki and approved by the Local
Ethical Committee.
Electroretinography
PhNR was recorded binocular with corneal Dawson-
Trick-Litzkow (DTL) electrodes. The reference elec-
trodes were placed on a lateral canthi, and the ground
electrode was attached to the centre of a forehead.
Before the examination pupils were dilated by 10 %
neosynephrine and 1 % tropicamide to minimum of 8
millimetres in diameter. Eyes were then adapted to the
background light for 10 min. Stimulus conditions: a
brief 4-ms red flash (640 nm, 400 cd/m2) at an
intensity of 1.6 cd s/m2 against the blue background
(450 nm) of 25 cd/m2 (photopic units). Signals were
amplified and filtered with the band-pass filter of
1–300 Hz and recorded with full-field LED stimulator
(RETI-port Roland Consult, 2003, Brandenburg, Ger-
many). Forty responses were averaged, and the mean
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curve was analysed. The PhNR amplitude was mea-
sured from the baseline to the trough of negative peak
following the b-wave (Fig. 1). PhNR/b-wave ampli-
tude ratio was also calculated. This is a modified
methodology of PhNR recording used by Viswanathan
et al. [8, 9] and other authors [10, 13].
Statistical analysis
Normality of data distribution was checked using the
Shapiro–Wilk test. The results of two independent
groups with normal distributed data were compared
using Student’s t test. When at least one of the
Table 1 Groups characteristic: age, distance best corrected visual acuity, mean defect and nerve fibre indicator in patients with
different stages of glaucomatous optic neuropathy and control groups
n Age (y) DBCVA MD (dB) NFI
POAG 1 30 64.7 ± 9.7 0.03 ± 0.09 -1.6 ± 1.5 30.0 ± 13.9*
C 30 63.7 ± 9.1 0.03 ± 0.07 -1.0 ± 2.1 17.2 ± 6.4
POAG 2 30 67.0 ± 7.0 0.03 ± 0.09 -6.1 ± 2.5*** 37.2 ± 18.9***
C 30 66.7 ± 7.8 0.05 ± 0.1 -1.2 ± 2.1 17.7 ± 7.7
POAG 3 30 66.8 ± 7.1 0.13 ± 0.15 -19.3 ± 6.8*** 62.1 ± 24.3***
C 30 65.8 ± 7.3 0.06 ± 0.1 -1.1 ± 2.1 16.9 ± 7.8
Statistical significance: * p\ 0.05; ** p\ 0.01; *** p\ 0.001; POAG 1 early primary open angle glaucoma, POAG 2 moderate
primary open angle glaucoma, POAG 3 advanced primary open angle glaucoma, C control group, DBCVA distance best corrected
visual acuity, MD, mean defect, NFI nerve fibre indicator, data are presented as mean ± standard deviation
Fig. 1 Representative
traces of reduced PhNR
amplitudes obtained from
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compared groups had not normal data distribution, the
Mann–Whitney test was applied. Correlations of
selected pairs were checked by calculating the Spear-
man’s correlation coefficient, because of not normal
data distribution. To avoid inter-eye correlation, one
eye from the same subject was randomly selected for
analyse. Sensitivity and specificity of PhNR amplitude
and ratio were calculated according to standard
formulas. ROC curve was calculated in order to
determine the cut-off point, for which the sensitivity
and specificity of the test were the highest. The
classification quality for PhNR was determine by
measuring the area under the ROC curve—AUC. The
level of significance of the test was set at 0.05.
Results
Statistically significant reduction of PhNR amplitudes
and ratios was observed in early, moderate and
advanced glaucoma group. In Table 2 the mean PhNR
amplitudes and ratios in POAG groups in comparison
with control groups are shown. In Fig. 1 representative
traces of PhNR in all presented stages of glaucomatous
neuropathy are shown.
When glaucomatous groups were compared
between each other, no differences between means
of PhNR amplitude and ratio in the early and moderate
glaucoma groups (p[ 0.05), as well as between
moderate and advanced glaucoma groups (p[ 0.05),
were found. However, statistically significant differ-
ence was noticed between early and advanced group
(p\ 0.05).
Statistically significant correlation between the
mean defect (SAP) and PhNR amplitude (r = 0.41,
p = 0.004) and PhNR ratio (r = 0.36, p = 0.01) in
glaucomatous patients was observed (Fig. 2). PhNR
amplitude and ratio correlated significantly with NFI
(r = -0.35, p = 0.01 for PhNR amplitude;
r = -0.38, p = 0.006 for PhNR ratio). Correlations
between structural parameter measured by GDx and
PhNR are shown in Fig. 2.
Figure 3a illustrates ROC curves for PhNR ampli-
tudes and ratios in early glaucoma group. Cut-off
value for PhNR amplitude was equal to 10.9 lV and
0.3 for PhNR ratio. Using this point, the test had
53.3 % sensitivity and could estimate healthy from
glaucoma patients with specificity equal to 90.0 %.
For PhNR ratio, 70.0 % sensitivity and 60.0 %
specificity were obtained.
In moderate glaucoma group cut-off values were
equal to 14.0 lV for PhNR amplitude and 0.2 for
PhNR ratio. PhNR sensitivity and specificity were
equal to 63.3 and 80.0 % for amplitude and 60.0 and
86.7 % for ratio, respectively. AUC for amplitude and
ratio was 0.8 (Fig. 3b).
In advanced glaucoma group cut-off values were
again equal to 14.0 lV for PhNR amplitude and 0.2
for PhNR ratio. PhNR sensitivity and specificity were
equal to 76.7 and 90.0 % for amplitude and 80.0 and
73.3 % for ratio, respectively. AUC for amplitude and
ratio reached 0.9 (Fig. 3c).
There were no significant differences between
AUCs for PhNR amplitude (0.76–0.86) and PhNR
ratio (0.78–0.86) between groups of patients, p[
0.05.
Discussion
The results of the presented study indicate that the
PhNR recorded with the modified protocol of
Viswanathan et al. [9] reveals the dysfunction of
RGCs in patients with different stages of glaucoma-
tous optic neuropathy. RGC function decreases grad-
ually with severity of glaucomatous visual field loss.
The mean PhNR amplitude and ratio were reduced
in early, moderate and advanced glaucomatous groups
compared to healthy control. Even in patients with
early glaucomatous optic neuropathy (POAG 1),
PhNR reduction was significant and equal to 38 %.
There are only two study results on PhNR in early
Table 2 PhNR mean amplitudes and ratios in examined
groups of patients
n A PhNR [lV] PhNR ratio
POAG 1 30 13.3 ± 9.2*** 0.15 ± 0.1***
C 30 25.8 ± 15.7 0.35 ± 0.21
POAG 2 30 13.4 ± 11.8*** 0.16 ± 0.13***
C 30 21.6 ± 11.2 0.31 ± 0.18
POAG 3 30 9.0 ± 6.1*** 0.13 ± 0.13***
C 30 22.1 ± 11.0 0.32 ± 0.17
Statistical significance: *** p\ 0.001; POAG 1 early primary
open angle glaucoma, POAG 2 moderate primary open angle
glaucoma, POAG 3 advanced primary open angle glaucoma,
C control group,A amplitude,PhNR photopic negative response,
data are presented as mean ± standard deviation
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Fig. 2 Scatter plots
showing relationships
between PhNR amplitude
and mean defect (MD) (a);
PhNR ratio and MD (b);
PhNR amplitude and NFI
(c) and between PhNR ratio
and NFI (d) in glaucomatous
group
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glaucoma [14, 19]. North et al. [14] described 22 % of
PhNR reduction compared to the control group with
similar visual field loss measured by static automated
perimetry (MD = -1.89 dB). Preiser et al. [19] found
that even in patients with preperimetric glaucoma
(average MD = 0.4 dB), reduction of the mean PhNR
amplitude albeit not significant was noticed.
Statistically significant (p = 0.0018) changes were
observed only in glaucomatous group with greater
mean sensitivity loss (average MD = -4.48 dB).
There is only one research published by Machida
et al. [20], who measured PhNR amplitudes in
moderate (average MD = -8.8 dB) and advanced
(average MD = -17.4 dB) optic neuropathy groups.
Fig. 3 Receiver operating
characteristic (ROC) curves
for the PhNR amplitude
(left) and PhNR ratio (right)
in early (a), moderate (b) and
advanced glaucoma (c)
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They found 37 and 51 %, respectively, of mean PhNR
amplitude reduction compared to the control group.
These results are consistent with our data in the
presented study. On the other hand, Cursiefen et al.
[15] while examining patients with severe glaucoma-
tous visual field loss (average MD = -13.0 dB)
obtained a non-significant reduction of PhNR ampli-
tude compared to the controls. The causes of these
discrepancies are probable methodological differ-
ences: type of perimetry used for visual field testing
(Octopus), different conditions of PhNR registration
(white flash on a white background) and the type of
used electrodes (Henkes).
PhNR test is able not only to graduate dysfunction of
RGCs in different stages of glaucomatous optic
neuropathy but also to demonstrate improvement of
RGCs function after IOP reduction.Niyadurupola et al.
[21] showed that PhNR amplitude improved in eyes of
patients with different stages of glaucomatous optic
neuropathy after IOP reduction of at least 25 %. In
glaucoma patients, dysfunction of RGCs measured by
PhNR was partially reversible even in advanced stage
of the disease. The result of above-mentioned study
suggests that PhNRmight be a useful test inmonitoring
glaucomatous treatment.
Our results confirmed the occurrence of linear
correlation between PhNR and the MD of SAP, which
was previously described by Viswanathan et al. [9].
Other authors found that a curvilinear correlation
model was a better fit than a linear regression [13, 22].
The fact of the correlation between PhNR and visual
field defect in glaucomatous patients could be imple-
mented in diagnosis process.
In this study we conducted the first comparative
analysis of PhNR parameters and GDx (NFI). Statis-
tically significant negative correlations between PhNR
parameters and NFI were observed. There are few
publications results showing relationships between
PhNR and optic nerve structures measured by other
methods like OCT [13, 22] and HRT [14]. The
Table 3 Comparison of PhNR and GDx sensitivities, specificities and AUCs in different stages of glaucomatous optic neuropathy
POAG 1 POAG 2 POAG 3
A PhNR PhNR
ratio
GDx A PhNR PhNR
ratio
GDx A PhNR PhNR
ratio
GDx
Sensitivity (%) 38.1 [20] 23.8 [20] 23.0 [23] 59.3 [20] 40.7 [20] 80.0 [25] 66.7 [20] 69.7 [20] 90.1 [26]
57.0 [13] 53.0 [13] 61.0 [17] 88.0 [13] 65.0 [13] 92.9 [26] 89.0 [13] 93.0 [13] 100.0 [25]
76.0 [18] 83.0 [9]
82.0 [24]
53.3 70.0 50.0 63.3 60.0 63.3 76.7 80.0 86.7
Specificity (%) 92.3 [20] 97.4 [20] 62.0 [24] 92.3 [20] 97.4 [20] 92.3 [20] 97.4 [20]
91.0 [18] 90.0 [9]
95.0 [17]
96.0 [23]
90.0 60.0 96.7 80.0 86.7 93.3 90.0 73.3 93.3
MD ± SD (dB) 0.4 ± 0.2 [19]; -1.9 ± 0.4 [14]
-3.2 ± 1.0 [12]; -3.3 ± 1.6 [20]
POAG 1 [13, 17, 18, 23, 24]
-4.5 ± 5.7 [19]; -6.3 [9]
-8.9 ± 1.6 [20]; -9.4 ± 2.8 [25]
POAG 2 [13, 26]
-10.3 ± 6.3 [27]; -17.4 ± 4.5
[20]–20.5 ± 4.7 [25]
POAG 3[13, 26]
-1.6 ± 1.5 -6.1 ± 2.5 -19.3 ± 6.8
AUC 0.6 [19] 0.7 [20] 0.8 [24] 0.8 [19] 0.8 [20] 0.9–1.0 [26] 0.9 [20] 0.9 [20] 0.9–1.0 [26]
0.7 [12, 20] 0.8 [19] 0.9 [17, 18] 0.9 [20] 0.8 [19] 1.0 [27]
0.8 [14] 1.0 [9]
0.8 0.8 0.8 0.8 0.9 0.9
Mean defect of static perimetry is presented as mean ± standard deviation
POAG 1 early primary open angle glaucoma, POAG 2 moderate primary open angle glaucoma, POAG 3 advanced primary open
angle glaucoma, A amplitude, PhNR photopic negative response, GDx glaucoma detection, MD mean defect, SD standard deviation,
AUC area under the curve, bold letter: own data; square bracket numbers refer to the references list numbers
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occurrence of these correlations is the additional
indicator of the usefulness of PhNR in glaucoma
diagnosis.
Table 3 summarises the results of PhNR and GDx
parameters in different stages of glaucomatous optic
disc neuropathy obtained from our study in compar-
ison with data available in the literature. The sensi-
tivity and specificity in detecting early glaucoma with
PhNR (amplitude and ratio) ranged from 23.8 to
57.0 % and from 90.0 to 92.3 %, respectively [13, 20].
In moderate glaucoma, PhNR (amplitude and ratio)
has better diagnostic ability and can distinguish
glaucomatous eyes with sensitivity ranged from 40.7
to 88.0 %, whereas specificity reached 97.4 % [13,
20]. In advanced glaucoma, sensitivity of PhNR
(amplitude and ratio) ranged from 66.7 to 93.0 %
[13, 20], whereas specificity was equal to 92.3–97.4 %
[20]. This comparison showed the compatibility of our
results with previously published data.
Nowadays measurement of RNFL by GDx, HRT
and OCT is a valuable diagnostic method used in
glaucoma. From the presented comparison of the data
on PhNR and GDx in different stages of glaucomatous
optic neuropathy, it is apparent that the PhNR may be
equivalent to other diagnostic tests used in this
disease.
In conclusion PhNR is a relatively new test in
glaucoma diagnosis. It is worth mentioning that PhNR
is obtained objectively as opposed to perimetry, which
is heavily dependent on subject input. The results of
the present study confirm results of previous published
data indicating usefulness of PhNR in glaucoma
diagnosis. However, it should be confirmed on a
larger group of patients and a longer follow-up period.
Recently in our opinion, this examination could be
designed for glaucoma patients with low visual acuity,
difficult to cooperate and should be reserved for
diagnostically complicated cases.
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